When

Saturday, February 28, 2026

6:00 AM-8:00 AM ET

WheRE

Philadelphia, PA

Grand Ballroom Salon H (Level 5) 
Philadelphia Marriott Downtown

faculty
Brian Chernak, MD
Memorial Sloan Kettering Cancer Center
New York, New York
Matthew P. Giannetti, MD
Instructor, Harvard Medical School
Allergy and Immunology
Associate Director
Brigham and Women’s Hospital Mastocytosis Center
Boston, Massachusetts
Anne L. Maitland, MD, PhD
Associate Professor, Department of Medicine - Rheumatology
Medical Director, The Ehlers Danlos Institute
Medical University of South Carolina
Charleston, South Carolina

 

6:00-6:30am ET - Registration & Breakfast

6:30-8:00am ET - Educational Program

Breakfast will be provided. 

 

Program Description

Start your morning with an immersive CME COMPETE™ activity, where education meets friendly competition. This interactive, case-based program energizes clinicians as they refine their approach to diagnosing and managing nonadvanced systemic mastocytosis (SM). Learners will navigate scenario-driven challenges that emphasize the importance of high-sensitivity molecular assays, accurate disease classification, and effective use of patient-reported outcomes. Expert faculty will guide teams through current therapeutic options, including approved targeted agents and late-stage investigational therapies shaping the evolving SM landscape. By earning points through data-driven decision-making, participants will strengthen their ability to individualize care and improve outcomes for patients living with nonadvanced SM. 

Target Audience

This activity is designed to educate a primary audience of allergy/immunology, dermatology, and related clinicians attending and interested in AAAAI.

Educational Objectives

Upon completion of this activity, the participant should be better able to: 

  • Explain the pathophysiology of nonadvanced SM, including driver mutations, mast cell hyperactivation, and the scientific rationale for targeted therapy. 
  • Apply updated diagnostic criteria (World Health Organization [WHO]/International Consensus Classification [ICC]) and integrate clinical cues, biomarkers, and genetic testing to improve timely and accurate diagnosis. 
  • Summarize current and emerging therapies for nonadvanced SM, including trial evidence and FDA-approved targeted treatments. 
  • Develop personalized treatment strategies that balance efficacy, safety, patient-reported outcomes, shared decision-making, and patient education, including trigger avoidance, anaphylaxis preparedness, and access to advocacy/resources. 

Americans With Disabilities Act

Event staff will be glad to assist you with any special needs (ie, physical, dietary, etc). Please contact us prior to the live event at info@exchangecme.com.

Register Now

attend event
Related events
FEB
28
2026
CME Compete
0.00 CME

SM Challenge

Competing to Master the Management of NonAdvanced SM

Time: 6:30 AM-8:00 AM ET
Venue: Live Stream
Location: Live Stream
Faculty:
MAR
01
2026
Mechanisms to Medicine™
0.00 CME

Tackling Eosinophilic Disorders

A Focus on Eosinophilic Granulomatosis with Polyangiitis and Hypereosinophilic Syndrome

Time: 6:00 AM-8:00 AM ET
Venue: Philadelphia Marriott Downtown
Location: Philadelphia, Pennsylvania
Faculty: Anisha B. Dua, MD, MPH; Flavia Hoyte, MD; Michael E. Wechsler, MD, MMSc
MAR
01
2026
Mechanisms to Medicine™
0.00 CME

Tackling Eosinophilic Disorders

A Focus on Eosinophilic Granulomatosis with Polyangiitis and Hypereosinophilic Syndrome

Time: 6:30 AM-8:00 AM ET
Venue: Live Stream
Location: Live Stream
Faculty: Anisha B. Dua, MD, MPH; Flavia Hoyte, MD; Michael E. Wechsler, MD, MMSc